Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy

medRxiv(2024)10.1101/2024.01.03.24300770Source: DataRank Database

Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy is a research paper published in medRxiv (2024). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:OA: greenIDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Gregory Sahagian ORCID,Marc H. Feinberg,Charles A. Stewart ORCID,Christopher M. Jewell ORCID,Metin Kurtoğlu

Live enrichment

PubMed:21097893

green

repositoryhttps://www.medrxiv.org/content/medrxiv/early/2024/01/04/2024.01.03.24300770.full.pdf

repositoryhttps://mdsoar.org/bitstreams/9047a626-ebf2-4121-ab40-9b54fa1001e0/download

Related Papers (10)

Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy

N/A

0.757DataRank · unranked

Journal of the American College of Cardiology(2021)

co-cited

10.1016/j.jacc.2021.08.044

CRISPR-enhanced human adipocyte browning as cell therapy for metabolic disease

Nature Communications(2021)

co-cited

10.1038/s41467-021-27190-y

Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion

Nature Reviews Clinical Oncology(2022)

co-cited

10.1038/s41571-022-00607-3

In vivo killing of primary HIV-infected cells by peripheral-injected early memory–enriched anti-HIV duoCAR T cells

N/A

1.1DataRank · unranked

JCI Insight(2022)

co-cited

10.1172/jci.insight.161698

Targeting SARS‐CoV ‐2 infection through CAR‐T ‐like bispecific T cell engagers incorporating ACE2

N/A

0.695DataRank · unranked

Clinical & Translational Immunology(2022)

co-cited

10.1002/cti2.1421

HIV-Specific CAR T Cells with CD28 or 4-1BB Signaling Domains Are Phenotypically and Functionally Distinct and Effective at Suppressing HIV and Simian Immunodeficiency Virus

N/A

0.385DataRank · unranked

ImmunoHorizons(2022)

co-cited

10.4049/immunohorizons.2200073

Direct reprogramming of cardiomyocytes into cardiac Purkinje-like cells

N/A

0.493DataRank · unranked

iScience(2022)

co-cited

10.1016/j.isci.2022.105402

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

N/A

5.4DataRank · unranked

The Lancet Neurology(2023)

co-cited

10.1016/s1474-4422(23)00194-1

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

N/A

3.4DataRank · unranked

Cell(2023)

co-cited

10.1016/j.cell.2023.08.041

Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells

N/A

4.4DataRank · unranked

Nature Biotechnology(2023)

co-cited

10.1038/s41587-022-01637-z